Innovation in Liver Disease Assessment
Nordic Bioscience has made a remarkable advancement in the field of liver disease with the launch of its PRO-C3 test in collaboration with Roche Diagnostics. This launch marks a significant milestone for both companies, as the test becomes available on Roche's cobas analysers, effectively enhancing the diagnostic capabilities in liver health assessment.
Understanding the PRO-C3 Test
The Roche Elecsys® PRO-C3 test provides an insightful evaluation of liver fibrosis severity using a holistic formula that incorporates age, diabetes status, PRO-C3 levels, and platelet counts. This innovative approach is crucial as liver diseases lead to approximately one in every 25 deaths globally. By enabling early and accurate detection through this advanced test, Nordic Bioscience and Roche are paving the way for improved patient management and treatment outcomes.
Commitment to Precision Medicine
Nordic Bioscience's dedication to precision medicine is evident through its validated biomarker PRO-C3, which has undergone rigorous testing in its CAP-CLIA certified laboratory. This commitment ensures that healthcare providers can rely on high-quality diagnostic tools, enhancing the potential for regulatory approvals and successful treatment strategies.
Extensive Research and Development
With over a decade of extensive research, Nordic Bioscience has published more than 250 scientific papers focused on the PRO-C3 biomarker. This remarkable depth of knowledge establishes the company as a leader in the research of PRO-C3 and fibrotic diseases, positioning it as a vital partner in the healthcare community.
The Importance of Biomarkers in Healthcare
PRO-C3 is the first biomarker emerging from Nordic Bioscience's fibrosis panel to receive CE approval. The relevance of such biomarkers cannot be understated, as organ alterations, particularly in the liver, correlate to 40% of deaths in the western world. By providing reliable tools for quantifying these alterations, Nordic Bioscience is at the forefront of modern clinical chemistry.
CEO's Vision for Patients
Morten Karsdal, the CEO of Nordic Bioscience, has expressed pride in the global impact of their technology. He emphasizes, "The Elecsys PRO-C3 test is the first test launched from the collaboration between Nordic Bioscience and Roche Diagnostics. We are proud that our technology becomes globally available to make a difference for patients." This visionary approach reaffirms the commitment to enhancing patient care through innovative diagnostics.
About PRO-C3 and Nordic Bioscience
PRO-C3 was initially developed as a specialized service within Nordic Bioscience's laboratory. With the collaboration now formalized through a license agreement with Roche Diagnostics, the Elecsys PRO-C3 test signifies a new era for the biomarker. In addition, Nordic Bioscience continues to leverage its unique neoepitope technology to further biomarker development across various clinical applications.
Nordic Bioscience, headquartered in Herlev, is strategically committed to advancing biomarker development that aligns both preclinical and clinical research efforts. This unique combination of expertise aims to fast-track decision-making processes regarding compound selection throughout clinical trials while also delivering substantial value in diagnostic settings for patients. By focusing on innovative solutions, Nordic Bioscience seeks to revolutionize the way biomarkers influence health outcomes.
For inquiries related to products or additional information, feel free to reach out through their contact platform, ensuring all stakeholders remain informed and engaged in the developments surrounding PRO-C3 and other groundbreaking initiatives.
Frequently Asked Questions
What is the PRO-C3 test?
The PRO-C3 test is a diagnostic tool developed by Nordic Bioscience that assesses liver fibrosis severity, aiding in the management of liver diseases.
Who launched the PRO-C3 test?
The PRO-C3 test was launched by Nordic Bioscience in collaboration with Roche Diagnostics on their cobas analysers.
Why is the PRO-C3 test significant?
This test is significant as it provides a reliable method for assessing liver fibrosis, which is crucial in reducing mortality associated with liver diseases.
What is Nordic Bioscience's role?
Nordic Bioscience is a biomarker development company that focuses on creating innovative solutions for precision medicine and liver disease management.
How does the PRO-C3 test contribute to patient care?
The test enhances early detection and evaluation of liver conditions, empowering healthcare providers to make informed treatment decisions and improve patient outcomes.
